Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squi...() as well as revenue from bulk efavirenz...)

included in the combination therapy ATRIPLA(TM), which is sold through

a joint venture in the U.S., Canada and Europe with Gilead Sciences,

Inc.

-- Sales of BARACLUDE(R), an oral antiviral agent for the treatment of

chronic hepatitis B, increased 140% to $108 million in the first

quarter of 2008 from $45 million in the same period in 2007, due to

continued growth across all markets.

-- Sales of ORENCIA(R), a fusion protein indicated for rheumatoid

arthritis, increased 112% to $87 million in the first quarter of 2008

from $41 million in the same period in 2007, primarily due to strong

growth in the U.S.

-- Sales of ERBITUX(R), which is sold by the company almost exclusively in

the U.S., increased 17% to $187 million in the first quarter of 2008

from $160 million in the same period in 2007, due to growth in the use

for head and neck and colorectal cancer. ERBITUX(R) is marketed by the

company under a distribution and copromotion agreement with ImClone

Systems Incorporated.

-- Sales for SPRYCEL(TM), an oral inhibitor of multiple tyrosine kinases

and indicated for treatment of chronic myeloid leukemia, increased to

$66 million in the first quarter of 2008 from $21 million in the same

period in 2007. This growth was driven by additional launches in

various international markets as well as growth in the U.S.

-- Sales of IXEMPRA(TM), a microtubule inhibitor for the treatment of

patients with metastatic or locally advanced breast cancer, were $25

million in the first quarter of 2008. IXEMPRA(TM) was launched in the

U.S. in October 2007.

MEAD JOHNSON NUTRITIONALS, CONVATEC PERFORMANCE

MEAD JOHNSON NUTRITIONALS

-- Worldwide Nutritional sales increased 16%, including a 5% favorable

fore
'/>"/>